Recent Updates — AVBP
ArriVent BioPharma announced initial Phase 1 data for its cadherin-17-targeted antibody-drug conjugate, ARR-217 (MRG007), presented at the ESMO Congress 2026. At a dose of 6 mg/kg every three weeks, the drug achieved a 44.8% objective response rate in heavily pretreated colorectal cancer patients and a 93.1% disease control rate. The treatment was generally well-tolerated with no grade 5 adverse events observed. ArriVent plans to advance ARR-217 into a Phase 1b dose optimization study, with further data expected in 2027. ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics.
ArriVent BioPharma announced it has dosed the first patient in a U.S. Phase 1 clinical trial for ARR-002, a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate designed to treat ovarian and endometrial cancer. The company noted that both targets are highly over-expressed in these cancers, with the dual-targeting approach intended to overcome limitations of single-target ADCs regarding heterogeneous target expression. ARR-002 is ArriVent's second ADC to enter clinical testing, expanding its pipeline beyond lung and gastrointestinal cancers. In August 2026, ArriVent licensed ARR-002 in Greater China to Shanghai Allist Pharmaceuticals while retaining rights elsewhere. The Phase 1 trial aims to evaluate the safety, tolerability, efficacy, and pharmacokinetics of the drug in patients with advanced or metastatic disease. ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics.
ArriVent BioPharma announced that its Phase 3 FURVENT trial evaluating firmonertinib monotherapy in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet the primary endpoint of progression-free survival by blinded independent central review. While secondary endpoints showed clinical benefit, including a confirmed objective response rate of 60% for the 240mg dose versus 33% for control, the drug failed to demonstrate a statistically significant improvement over chemotherapy in the primary measure. The company is evaluating the full dataset to determine the future development path for firmonertinib. ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer.
ArriVent BioPharma entered into a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals for ARR-002 in Greater China. The deal includes up to $80.6 million in potential payments, comprising an upfront sum and milestone-based amounts, plus mid-single digit to low double-digit tiered royalties on net sales. ArriVent retains global rights outside the region and will supply initial clinical study material. Concurrently, the company reported second quarter 2026 financial results showing a net loss of $93.2 million for the six months ended June 30, 2026, compared to $95.8 million in the prior year period. Cash and investments totaled $373.1 million as of June 30, 2026, expected to fund operations into 2028. ArriVent BioPharma is a clinical-stage biopharmaceutical company developing innovative cancer therapeutics.